It’s Not Over Yet For Coherus Biosciences Inc (NASDAQ: CHRS)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

Coherus Biosciences Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $2.32 and fluctuated between $2.3300 as its day high and $1.9701 as its day low. The current market capitalization of Coherus Biosciences Inc is $258.36M. A total of 4.25 million shares were traded on the day, compared to an average of 7.03M shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, CHRS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 3 SELLs from insiders. Insiders purchased 0 shares during that period but sold 22,186.

In the most recent transaction, Lanfear Dennis M sold 223,100 shares of CHRS for 2.02 per share on Nov 22. After the transaction, the President & CEO now owns 731,693 company shares.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for CHRS in the last 3 months, the mean price target is $11.67 with high estimates of $23.00 and low estimates of $7.00. In terms of 52-week highs and lows, CHRS has a high of $8.65 and a low of $1.43.

As of this writing, CHRS has an earnings estimate of -$0.14 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $0.52 per share and a lower estimate of -$0.37. The company reported an EPS of -$0.38 in the last quarter, which was 20.80% higher than expectations of -$0.48.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CHRS’s latest balance sheet shows that the firm has $417.19M in Cash & Short Term Investments as of fiscal 2021. There were $419.02M in debt and $165.33M in liabilities at the time. Its Book Value Per Share was -$1.22, while its Total Shareholder’s Equity was $97.73M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CHRS is Buy with a score of 4.40.

Most Popular

Related Posts